Similar articles

• [The use of Cardioxane in chemotherapy of malignant neoplasms in children].

  Safonova SA, Punanov IuA, Dedukh VM, Kolygin BA. Safonova SA, et al. Vopr Onkol. 1997;43(4):459-61. Vopr Onkol. 1997. PMID: 9381706 Russian.
• Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.

  Anderson B. Anderson B. Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8. doi: 10.1002/pbc.20358. Pediatr Blood Cancer. 2005. PMID: 15700251 Review.
• Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?

  Silber JH. Silber JH. Nat Clin Pract Oncol. 2004 Nov;1(1):16-7. doi: 10.1038/ncponc0023. Nat Clin Pract Oncol. 2004. PMID: 16264791 No abstract available.
• Doxorubicin-induced cardiomyopathy.

  Muggia FM, Speyer JL. Muggia FM, et al. N Engl J Med. 1999 Feb 25;340(8):654-5. N Engl J Med. 1999. PMID: 10049088 No abstract available.
• Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.

  Pouillart P. Pouillart P. Cancer Treat Rev. 2004 Nov;30(7):643-50. doi: 10.1016/j.ctrv.2004.06.002. Cancer Treat Rev. 2004. PMID: 15531396 Review.